NSE: GLAND | BSE: 543245

Strong Performer, Getting Expensive

Download real time

2984.00 -5.70 (-0.19%)

Near 52W High of ₹3042.00

128.3K NSE+BSE Volume

NSE 30 Sep, 2026 10:19 AM (IST)

49,239.3

Market Cap

High in industry

Beta 1Year

Very Low volatility

Policy Tailwind

Gland Pharma rises after the US announces zero-duty on select specialty medicines from India See details

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

10 Aug 2026

2984.00

-0.19%

US, EU strength drives 5-9% beat

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered a better-than-expected financial performance in 1QFY27, with 5%/9%/9% beat on revenue/EBITDA/PAT.

Gland Pharma has gained 25.75% in the last 3 Months

Gland Pharma Ltd.

22 May 2026

2984.00

-0.19%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in...

Number of FII/FPI investors increased from 230 to 286 in Jun 2026 qtr.

Gland Pharma Ltd.

29 Jan 2026, 12:00AM

2984.00

-0.19%

Result Update:Gland Pharma

Buy: Gland Pharma Ltd.

Recommendation

Axis Direct

We maintain our BUY rating on the stock.

Gland Pharma Ltd. has an average target of 2631.67 from 3 brokers.

Gland Pharma Ltd.

29 Jan 2026, 12:00AM

2984.00

-0.19%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

Gland Pharma has gained 73.08% in the last 6 Months

Gland Pharma Ltd.

28 Jan 2026

2984.00

-0.19%

Cenexi break-even/US uptrend drives earnings beat

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered better-than-expected 3QFY26 financial performance with a 6%/14%/19% beat on revenue/EBITDA/PAT.

Gland Pharma Ltd. has an average target of 2631.67 from 3 brokers.

Gland Pharma Ltd.

04 Nov 2025

2984.00

-0.19%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We revise our rating from HOLD to BUY

Gland Pharma Ltd. is trading above all available SMAs

Gland Pharma Ltd.

04 Nov 2025

2984.00

-0.19%

Gland Pharma

Buy: Gland Pharma Ltd.

ICICI Direct

Gland Pharma has gained 73.08% in the last 6 Months

Gland Pharma Ltd.

04 Nov 2025

2984.00

-0.19%

In-line revenue; margin miss transient

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lowerthan-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance.